Saratoga Research & Investment Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,448
| Closed | -$221K | – | 45 |
|
|
2024
Q4 | $221K | Sell |
1,448
-149,272
| -99% | -$25.2M | 0.01% | 43 |
|
|
2024
Q3 | $29.2M | Sell |
150,720
-7,071
| -4% | -$1.48M | 1.28% | 25 |
|
|
2024
Q2 | $36.6M | Sell |
157,791
-5,060
| -3% | -$1.1M | 1.66% | 23 |
|
|
2024
Q1 | $35.1M | Sell |
162,851
-1,375
| -0.8% | -$322K | 1.6% | 23 |
|
|
2023
Q4 | $42.5M | Sell |
164,226
-11,838
| -7% | -$2.91M | 1.96% | 22 |
|
|
2023
Q3 | $45.3M | Sell |
176,064
-2,979
| -2% | -$797K | 2.21% | 22 |
|
|
2023
Q2 | $51M | Sell |
179,043
-4,286
| -2% | -$1.28M | 2.35% | 22 |
|
|
2023
Q1 | $51M | Sell |
183,329
-720
| -0.4% | -$199K | 2.42% | 21 |
|
|
2022
Q4 | $51M | Sell |
184,049
-47,356
| -20% | -$13.4M | 2.52% | 22 |
|
|
2022
Q3 | $61.8M | Sell |
231,405
-1,065
| -0.5% | -$226K | 3.27% | 15 |
|
|
2022
Q2 | $47.4M | Sell |
232,470
-7,978
| -3% | -$1.63M | 2.35% | 23 |
|
|
2022
Q1 | $50.6M | Buy |
240,448
+5,257
| +2% | +$1.14M | 2.2% | 24 |
|
|
2021
Q4 | $56.4M | Sell |
235,191
-5,133
| -2% | -$1.32M | 2.4% | 23 |
|
|
2021
Q3 | $68M | Sell |
240,324
-729
| -0.3% | -$239K | 3.14% | 14 |
|
|
2021
Q2 | $83.5M | Sell |
241,053
-13,128
| -5% | -$3.98M | 3.94% | 10 |
|
|
2021
Q1 | $71.1M | Buy |
254,181
+7,481
| +3% | +$2.02M | 3.6% | 12 |
|
|
2020
Q4 | $60.4M | Buy |
246,700
+7,625
| +3% | +$1.97M | 3.24% | 15 |
|
|
2020
Q3 | $67.8M | Sell |
239,075
-4,021
| -2% | -$1.12M | 4.07% | 8 |
|
|
2020
Q2 | $65M | Sell |
243,096
-2,842
| -1% | -$854K | 4.11% | 11 |
|
|
2020
Q1 | $77.8M | Buy |
245,938
+2,519
| +1% | +$764K | 5.39% | 7 |
|
|
2019
Q4 | $72.2M | Buy |
243,419
+1,274
| +0.5% | +$353K | 4.33% | 10 |
|
|
2019
Q3 | $56.4M | Buy |
242,145
+2,158
| +0.9% | +$502K | 3.64% | 13 |
|
|
2019
Q2 | $56.1M | Buy |
239,987
+79,307
| +49% | +$18.3M | 3.53% | 14 |
|
|
2019
Q1 | $38M | Buy |
160,680
+14,774
| +10% | +$4.65M | 2.59% | 16 |
|
|
2018
Q4 | $43.9M | Sell |
145,906
-8,821
| -6% | -$2.82M | 3.48% | 15 |
|
|
2018
Q3 | $54.7M | Sell |
154,727
-5,246
| -3% | -$1.81M | 3.69% | 13 |
|
|
2018
Q2 | $46.4M | Sell |
159,973
-225
| -0.1% | -$63.3K | 3.33% | 13 |
|
|
2018
Q1 | $43.9M | Buy |
160,198
+14,439
| +10% | +$4.48M | 3.21% | 14 |
|
|
2017
Q4 | $46.4M | Buy |
145,759
+4,250
| +3% | +$1.36M | 3.25% | 12 |
|
|
2017
Q3 | $44.3M | Buy |
141,509
+3,947
| +3% | +$1.17M | 3.39% | 12 |
|
|
2017
Q2 | $37.3M | Buy |
137,562
+11,340
| +9% | +$3M | 2.97% | 15 |
|
|
2017
Q1 | $34.5M | Buy |
126,222
+5,896
| +5% | +$1.67M | 2.87% | 16 |
|
|
2016
Q4 | $34.1M | Sell |
120,326
-2,246
| -2% | -$666K | 3.08% | 15 |
|
|
2016
Q3 | $38.4M | Buy |
122,572
+3,237
| +3% | +$959K | 3.29% | 14 |
|
|
2016
Q2 | $28.9M | Buy |
119,335
+27,026
| +29% | +$7.12M | 2.59% | 21 |
|
|
2016
Q1 | $24M | Buy |
92,309
+91,518
| +11,570% | +$24.2M | 2.12% | 24 |
|
|
2015
Q4 | $242K | Buy |
+791
| New | +$227K | 0.02% | 47 |
|
Other funds holding BIIB
Saratoga Research & Investment Management's BIIB Position: Q1 2025 in Review
Saratoga Research & Investment Management sold out of Biogen (BIIB) in Q1 2025, closing a stake of 1,448 shares — an estimated $221K sold.
Saratoga Research & Investment Management first reported a position in BIIB in Q4 2015 and held it in 37 quarters. The position peaked at $83.5M in Q2 2021. 882 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.
- Saratoga Research & Investment Management reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
- Saratoga Research & Investment Management sold 1,448 Biogen shares in Q1 2025, an estimated $221K.
- Saratoga Research & Investment Management first reported a position in Biogen in Q4 2015 and held it in 37 quarters.
- Saratoga Research & Investment Management's Biogen position peaked at $83.5M in Q2 2021.
- 882 funds tracked by Wall St. Rank held Biogen as of Q1 2025.
Based on Saratoga Research & Investment Management's 13F filing for Q1 2025, filed 12 May 2025.